[c-Met and HGF expression in non-small-cell lung carcinomas]
Molekuliarnaia Genetika, Mikrobiologiia I Virusologiia
|June 30, 2007
Summary
The c-Met receptor, not its ligand HGF, is frequently altered in non-small cell lung carcinomas, particularly adenocarcinomas. This finding suggests c-Met may indicate tumor progression and aggressive behavior in lung cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Alterations in the c-Met/HGF system are implicated in various tumor progressions.
- The c-Met/HGF pathway plays a role in lung tumor development.
- Aberrant expression of c-Met and HGF is noted in non-small cell lung carcinomas (NSCLC).
Purpose of the Study:
- To investigate and compare the expression levels of c-Met and HGF in NSCLC tissues versus adjacent non-malignant tissues.
- To determine the prevalence of c-Met and HGF alterations in different subtypes of NSCLC.
Main Methods:
- Semi-quantitative PCR was employed to analyze gene expression.
- Expression levels of c-Met and HGF transcripts were quantified.
- Comparisons were made between tumor samples and adjacent non-malignant lung tissues.
Main Results:
- c-Met transcript was detected in 50% of squamous cell carcinoma samples, with elevated levels in 8%.
- HGF transcript was rarely detected in squamous cell carcinomas (only 2 cases).
- c-Met transcript was observed in all 5 adenocarcinoma samples, with increased levels in 3 cases; HGF was found in 2 samples.
Conclusions:
- c-Met transcript is more frequently observed and often elevated in non-small cell lung carcinomas, especially adenocarcinomas, compared to HGF.
- The study highlights c-Met as a potentially significant indicator of aggressive behavior and progression in NSCLC, aligning with other research findings.
